News

Article

Disparities in Kidney Transplant Waitlisting, with Syed Ali Husain, MD, MPH

Syed Ali Husain, MD, MPH, discusses the importance of kidney transplantation, waitlisting, and how disparities in access to transplantation should be addressed.

Disparities based on sex, race, ethnicity, and employment status may play a role in the kidney transplant waitlisting process, as highlighted by findings from a recent retrospective cohort study of ≥50,000 patients with end-stage kidney disease on dialysis.1

Using data from the US Renal Data System Registry, investigators identified 52,902 patients aged ≤40 years with no major medical comorbidities who initiated dialysis between January 1, 2005, and December 31, 2019, and examined time to waitlisting for a kidney transplant. Investigators categorized patients into 3 groups based on outcome: waitlisted <1 year after dialysis initiation, waitlisted 1-5 years after dialysis initiation, or not waitlisted within 5 years of dialysis initiation.1

In total, 15,840 (30%) patients were waitlisted within 1 year, 11,122 (21%) between 1-5 years, and 25,940 (49%) patients were not waitlisted within 5 years of dialysis initiation. Investigators noted sex and age impacted waitlisting, with increased age (subhazard ratio [SHR], .98 per year; 95% confidence interval [CI], .97 to .98; P < .001) and female sex (SHR, .92; 95% CI, .90 to .94; P <.001) associated with decreased waitlisting. Hispanic ethnicity (SHR, .77; 95% CI, .75 to .80; P < .001), Black race (SHR, .66; 95% CI, .64 to .68; P < .001), and unemployment (SHR, .47; 95% CI, .45 to .48; P < .001) were also associated with reduced waitlisting.1

The editorial team of HCPLive Nephrology sat down with primary investigator Syed Ali Husain, MD, MPH, assistant professor of medicine at Columbia University Medical Center, for more insight into chronic kidney disease, study results, and how waitlisting disparities can be improved moving forward.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.